ICON plc is a leading global contract research organization (CRO) that provides outsourced drug and device development and commercialization services to pharmaceutical, biotechnology, medical device, and government organizations. It specializes in full-service clinical trials from Phase I to IV, including complex multinational studies, cell and gene therapy, early phase research, late phase services, and real-world evidence generation across a broad range of therapeutic areas. ICON plc offers functional service provision (FSP) solutions, embedding dedicated teams within client operations for clinical monitoring, project management, data management, and statistical programming. The company delivers innovative technology solutions, AI, and data analytics to accelerate time to market, reduce costs, and enhance trial efficiency through site- and patient-centric approaches that optimize recruitment and retention. Additional services include medical imaging, pharmacovigilance, laboratory offerings, and consulting for market access and health economics. Founded in 1990 and headquartered in Dublin, Ireland, ICON plc supports the entire product lifecycle with a global presence, enabling faster delivery of treatments that improve lives.
Earnings calendar coming soon. Subscribe to get notified when ICLR reports next.
Get earnings alerts →